+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin



Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin



Acta Biochimica Polonica 59(3): 333-337



Hepatitis C virus (HCV) infection is a global health problem which can lead to liver cirrhosis or hepatocellular carcinoma in one-fifth of chronically infected patients. The study group consisted of 123 patients: 90 with HCV mono- and 33 with HIV/HCV co-infection, who were treated with pegylated interferon alfa (Peg-IFN-α) and ribavirin. We analyzed selected pretreatment factors: age, sex, HIV/HCV co-infection, grade of inflammation, necrotic changes and fibrosis in histological analysis of liver bioptates, HCV viral load, HCV genotypes, and single nucleotide polymorphisms (SNPs) of IL28B and tried to find out which of them influence sustained virological response (SVR). The IL28B SNP C/T (rs12979860) was analyzed using Custom(®) SNP Genotyping Assays (Applied Biosystems). Multivariate analysis demonstrated that after adjusting for the other variables three predictors independently influence SVR, namely genotype 3 of HCV, presence of the CC genotype and age >40 years (OR respectively 15.14, 3.62, and 0.36). HCV mono-infected patients were infected with HCV genotype 3 or 4 less frequently (p=0.0001) compared to HIV/HCV co-infected individuals. In patients with HIV/HCV co-infection the CC variant occurred more frequently whereas CT was found less frequently (p=0.001, p=0.0146, respectively). In patients with HIV/HCV co-infection, 3 and 4 genotype of HCV occurred more frequently compared to patients with HCV mono-infection (p=0.0001). These data suggest that age, HCV genotype and IL28B polymorphism are useful for prediction of the response to treatment with Peg-IFN-α and ribavirin. The more frequent occurrence of HCV genotypes 3 or 4 in patients with HIV/HCV co-infection could be associated with the route of transmission.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056048663

Download citation: RISBibTeXText

PMID: 22924160


Related references

Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepatitis Monthly 11(3): 163-172, 2011

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin. Journal of Hepatology 54(5): 866-871, 2011

A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. Memorias do Instituto Oswaldo Cruz 107(7): 888-892, 2013

A single nucleotide polymorphism, rs129679860, in the Il28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin. Memórias do Instituto Oswaldo Cruz 107(7): 888-892, 2012

IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis. Clinics and Research in Hepatology and Gastroenterology 39(5): 576-583, 2016

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon alfa-2a and interferon alfa-2a. Hepatology 32(4 Pt 2): 356A, 2000

Is sustained virologic response durable in patients with chronic hepatitis C treated with interferon alfa with or without ribavirin?. Journal of Hepatology 36(Suppl. 1): 103, 2002

Su1077 Vitamin D and B12 Supplementation and Sustained Virologic Response in Chronic Hepatitis C Patients Treated With Pegylated Interferon and Ribavirin. Gastroenterology 146(5): S-982, 2014

Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Journal of Proteome Research 10(2): 774-779, 2011

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean Journal of Hepatology 17(3): 183-188, 2012

W1005 Hcv Rna At 12 Weeks After Treatment Can Predict Sustained Virologic Response in Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin. Gastroenterology 134(4): A-830, 2008

PEG-INTERFERON alpha-2B + RIBAVIRIN FOR TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO HAVE PREVIOUSLY FAILED TO ACHIEVE A SUSTAINED VIROLOGIC RESPONSE FOLLOWING INTERFERON ALFA OR INTERFERON A-2B + RIBAVIRIN THERAPY. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No T1292, 2003

M1781 Rapid Virologic Response Predicts Sustained Virologic Response in Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin Therapy. Gastroenterology 136(5): A-836-A-837, 2009

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages. Przeglad Epidemiologiczny 60(4): 673-676, 2007

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Alimentary Pharmacology and Therapeutics 36(2): 91-103, 2012